Collplant Competitors

Stocks . USA . 
Stock . Collplant Biotechnologies
CLGN Stock  USD 3.27  0.11  3.48%   
Collplant Biotechnologies competes with Keros Therapeutics, Merus BV, Vericel Corp, Century Therapeutics, and Shattuck Labs; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Collplant Biotechnologies competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Collplant Biotechnologies to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Collplant Biotechnologies Correlation with its peers.
To learn how to invest in Collplant Stock, please use our How to Invest in Collplant Biotechnologies guide.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Collplant Biotechnologies competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.163.276.78
Details
Intrinsic
Valuation
LowRealHigh
0.183.517.03
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Collplant Biotechnologies. Your research has to be compared to or analyzed against Collplant Biotechnologies' peers to derive any actionable benefits. When done correctly, Collplant Biotechnologies' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Collplant Biotechnologies.

Collplant Biotechnologies Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Collplant Biotechnologies and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Collplant and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Collplant Biotechnologies does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
IPSC
+ 0.81
KROS
MOLN
+ 0.81
CCCC
PRLD
+ 0.75
IPSC
PRLD
+ 0.69
VCEL
GLUE
+ 0.63
KROS
IPSC
+ 0.61
VCEL
  
High negative correlations   
VCEL
- 0.76
MRUS
PRLD
- 0.66
MRUS
IPSC
- 0.51
MRUS
CCCC
- 0.45
MRUS
CCCC
- 0.38
STTK
MOLN
- 0.38
MRUS

Risk-Adjusted Indicators

There is a big difference between Collplant Stock performing well and Collplant Biotechnologies Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Collplant Biotechnologies' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
KROS  2.73 (0.81) 0.00  5.47  0.00 
 0.00 
 4.41 
(6.00)
 17.79 
MRUS  1.96  0.23  0.11  0.43  2.47 
(2.18)
 4.91 
(3.56)
 12.66 
VCEL  1.86 (0.23) 0.00 (0.34) 0.00 
 0.00 
 3.99 
(4.25)
 10.94 
IPSC  2.84 (0.90) 0.00 (0.80) 0.00 
 0.00 
 5.88 
(7.48)
 17.02 
STTK  5.45  0.49  0.07  0.63  6.71 
(6.72)
 11.21 
(7.58)
 50.15 
CCCC  3.57 (0.81) 0.00 (0.44) 0.00 
 0.00 
 7.10 
(8.28)
 20.72 
ELYM  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
PRLD  5.39  0.00  0.02 (0.03) 5.88 
(6.59)
 11.20 
(9.46)
 61.66 
GLUE  3.34 (0.14) 0.00 (0.24) 0.00 
 0.00 
 6.50 
(7.40)
 19.92 
MOLN  2.32 (0.18) 0.00 (0.21) 0.00 
 0.00 
 7.09 
(5.85)
 17.19 
All Fundamental Data

Collplant Biotechnologies Competitive Analysis

The better you understand Collplant Biotechnologies competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Collplant Biotechnologies' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Collplant Biotechnologies' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
CLGN KROS MRUS VCEL IPSC STTK CCCC PRLD GLUE MOLN
 3.48 
 3.27 
Collplant
 0.96 
 11.58 
Keros
 1.13 
 47.10 
Merus
 0.02 
 45.38 
Vericel
 7.14 
 0.60 
Century
 1.65 
 1.19 
Shattuck
 0.50 
 2.03 
CCCC
 4.23 
 0.74 
Prelude
 0.97 
 6.27 
Monte
 1.37 
 4.33 
Molecular
Market Volatility
(90 Days Market Risk)
Unstable
Not too volatile
Very steady
Very steady
Very risky
Abnormally volatile
Moderately volatile
Extremely Dangerous
Slightly risky
Slightly risky
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Modest
Very Weak
Very Weak
Insignificant
Very Weak
Very Weak
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Low
Below Average
Very Low
Very High
Below Average
Quite High
Very High
About Average
Low
Current Valuation
(Equity Enterprise Value)
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Strong Buy
Not Available
Not Available
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Cautious Hold
Strong Sell
Strong Hold
Hold
Strong Sell
Hold
Cautious Hold
Strong Sell
Cautious Hold
Hold
Current Ratio
16.21
14.39
6.62
6.2
17.79
9.46
6.9
15.73
20.11
14.37
Net Asset
34.13 M
615.89 M
782.69 M
432.72 M
360.69 M
159.56 M
349.6 M
175.51 M
303.75 M
158.53 M
Profit Margin
N/A
N/A
N/A
0.0437
N/A
N/A
-2.96
N/A
N/A
N/A
EBITDA
(6.41 M)
(185.82 M)
(269.6 M)
16.63 M
(121.21 M)
(87.61 M)
(115.36 M)
(139.71 M)
(137.09 M)
(51.65 M)
Current Valuation
22.93 M
(75.82 M)
2.76 B
2.25 B
(92.45 M)
(27.72 M)
(35.75 M)
(76.6 M)
183.03 M
(12.39 M)
Price To Book
2.07
0.81
5.08
7.77
0.26
0.61
0.66
0.3
1.86
0.99
Operating Margin
N/A
-17.51
-9.7
0.25
-43.98
-5.98
-7.28
-8.46
-2.88
-12.32
Retained Earnings
(96.74 M)
(568.78 M)
(968.39 M)
(392.81 M)
(655.77 M)
(306.31 M)
(633.7 M)
(583.56 M)
(365.89 M)
(246.29 M)
Current Asset
17.03 M
11.95 M
68 M
21.1 M
N/A
N/A
1 K
N/A
N/A
N/A
Beta
0.7
1.4
1.15
1.79
1.76
1.67
3.0
1.42
1.5
0.63
Number Of Employees
75
169
260
357
152
75
110
131
133
158
Shares Outstanding
11.45 M
40.56 M
69.09 M
49.97 M
85.03 M
47.74 M
70.99 M
42.3 M
61.44 M
36.87 M
Cash Flow From Operations
(2.76 M)
(160.87 M)
(185.84 M)
58.16 M
(88.35 M)
(81.23 M)
(65.16 M)
(102.89 M)
(43.8 M)
(59.25 M)
Total Debt
3.16 M
18.86 M
9.91 M
98.85 M
48.17 M
4.2 M
133.62 M
18.02 M
46.04 M
2.44 M
Return On Equity
-0.71
-0.41
-0.43
0.04
-0.63
-0.71
-0.46
-0.69
-0.61
-0.34
Return On Asset
-0.38
-0.27
-0.27
0.0072
-0.21
-0.41
-0.2
-0.39
-0.28
-0.21
Number Of Shares Shorted
6.38 K
4.13 M
6.64 M
3.61 M
3.13 M
1.92 M
8.06 M
3.1 M
8.03 M
42.6 K
Book Value Per Share
1.48
14.09
9.41
5.88
2.31
2.02
3.06
2.38
3.35
3.84
Current Liabilities
6.37 M
5.72 M
5 M
15.36 M
N/A
N/A
49 K
N/A
N/A
N/A
Total Asset
34.13 M
615.89 M
782.69 M
432.72 M
360.69 M
159.56 M
349.6 M
175.51 M
303.75 M
158.53 M
Debt To Equity
0.076
0.003
0.041
0.28
0.12
0.023
0.25
0.007
0.16
0.02
Short Ratio
0.89
3.86
13.03
10.37
7.13
7.83
4.7
11.06
17.6
26.8
Target Price
12.5
33.64
86.38
65.38
9.0
1.2
15.56
3.33
16.38
10.73
Shares Owned By Institutions
12.23
97.71
97.97
98.99
57.96
65.38
91.51
68.77
99.3
9.72
Market Capitalization
36.2 M
465.25 M
3.29 B
2.27 B
47.49 M
57.77 M
144.11 M
38.99 M
381.52 M
159.67 M
Price To Earning
92.6
N/A
-4.47
357.33
86.08
N/A
N/A
N/A
1.91
1.85
Price To Earnings To Growth
N/A
N/A
N/A
N/A
0.26
N/A
0.07
-0.09
N/A
N/A
Price To Sales
55.69
131.06
91.09
9.56
17.69
8.98
4.05
5.57
25.48
32.13
Net Income
(7.02 M)
(187.35 M)
(215.33 M)
10.36 M
(136.67 M)
(87.3 M)
(105.32 M)
(127.17 M)
(135.35 M)
(54.04 M)
Earnings Per Share
-1.53
-5.0
-3.35
0.2
-1.83
-1.53
-1.52
-1.68
-1.78
-1.8
Shares Owned By Insiders
10.1
2.29
2.03
1.01
28.06
14.3
11.51
7.19
0.7
N/A
Revenue
10.96 M
3.55 M
36.13 M
237.22 M
2.23 M
1.66 M
35.58 M
7 M
N/A
4.97 M
Working Capital
24.77 M
561.44 M
482 M
162.49 M
159.15 M
131.77 M
212.59 M
110.25 M
189.62 M
143.5 M
Cash And Equivalents
36.29 M
215.62 M
376.11 M
100.69 M
378.76 M
214.24 M
307.78 M
246.3 M
294.14 M
267.13 M
Cash Per Share
3.27
8.37
8.2
2.13
6.43
5.09
6.29
5.19
6.32
8.22
Gross Profit
(1.48 M)
(14.74 M)
13.42 M
172.11 M
(97.48 M)
(60.31 M)
(75.05 M)
7 M
16.78 M
(42.53 M)
Day Typical Price
3.25
11.62
47.67
45.93
0.59
1.19
2.02
0.76
6.27
4.34
Accumulation Distribution
0.0512
0.0212
0.0528
0.0405
0.13
0.0887
0.0483
0.0633
0.0467
0.0046
Market Facilitation Index
0.17
0.25
2.6
1.91
0.08
0.11
0.1
0.05
0.3
0.02
Daily Balance Of Power
0.6471
0.44
(0.21)
(0.01)
0.5
(0.18)
0.1
0.6
0.2
(3.00)
Period Momentum Indicator
0.11
0.11
(0.54)
(0.01)
0.04
(0.02)
0.01
0.03
0.06
(0.06)
Rate Of Daily Change
1.03
1.01
0.99
1.0
1.07
0.98
1.0
1.04
1.01
0.99
Day Median Price
3.24
11.65
47.95
46.21
0.59
1.19
2.02
0.77
6.27
4.34
Price Action Indicator
0.09
(0.01)
(1.12)
(0.83)
0.03
(0.01)
0.015
(0.01)
0.03
(0.04)
Coefficient Of Variation
(3,208)
(486.06)
1378.76
(719.48)
(368.27)
1758.03
(416.86)
73013.8
(1,761)
(920.69)
Mean Deviation
2.51
2.73
1.96
1.86
2.84
5.45
3.57
5.39
3.34
2.32
Jensen Alpha
(0.05)
(0.81)
0.2271
(0.23)
(0.90)
0.4926
(0.81)
(0)
(0.14)
(0.18)
Total Risk Alpha
0.32
(0.32)
0.512
(0.04)
(0.57)
1.37
(0.52)
1.08
0.2862
0.0459
Sortino Ratio
N/A
N/A
0.1101
N/A
N/A
0.067
N/A
0.0177
N/A
N/A
Downside Variance
N/A
N/A
6.96
N/A
N/A
62.45
N/A
38.99
N/A
N/A
Standard Deviation
3.51
3.81
2.64
2.41
3.81
7.56
4.47
8.57
4.33
3.36
Kurtosis
1.26
4.66
0.9846
0.2444
0.5891
2.72
(0.20)
13.26
0.237
1.31
Potential Upside
5.83
4.41
4.91
3.99
5.88
11.21
7.1
11.2
6.5
7.09
Treynor Ratio
(0.18)
5.47
0.4333
(0.34)
(0.80)
0.6327
(0.44)
(0.03)
(0.24)
(0.21)
Maximum Drawdown
17.19
17.79
12.66
10.94
17.02
50.15
20.72
61.66
19.92
17.19
Variance
12.3
14.49
6.97
5.8
14.51
57.19
20.0
73.51
18.71
11.31
Market Risk Adjusted Performance
(0.17)
5.48
0.4433
(0.33)
(0.79)
0.6427
(0.43)
(0.02)
(0.23)
(0.20)
Risk Adjusted Performance
(0.02)
(0.17)
0.0698
(0.11)
(0.23)
0.0584
(0.20)
0.0102
(0.04)
(0.09)
Skewness
0.4973
(1.53)
(0.20)
(0.24)
(0.05)
0.0157
0.1919
2.73
0.2302
0.3167
Semi Deviation
N/A
N/A
2.47
N/A
N/A
6.71
N/A
5.88
N/A
N/A
Information Ratio
(0)
(0.18)
0.1101
(0.1)
(0.25)
0.07
(0.22)
0.0129
(0.03)
(0.08)
Value At Risk
(6.05)
(6.00)
(3.56)
(4.25)
(7.48)
(7.58)
(8.28)
(9.46)
(7.40)
(5.85)
Expected Short fall
N/A
N/A
(2.18)
N/A
N/A
(6.72)
N/A
(6.59)
N/A
N/A
Downside Deviation
N/A
N/A
2.64
N/A
N/A
7.9
N/A
6.24
N/A
N/A
Semi Variance
N/A
N/A
6.09
N/A
N/A
44.97
N/A
34.52
N/A
N/A

Collplant Biotechnologies Competition Performance Charts

Five steps to successful analysis of Collplant Biotechnologies Competition

Collplant Biotechnologies' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Collplant Biotechnologies in relation to its competition. Collplant Biotechnologies' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Collplant Biotechnologies in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Collplant Biotechnologies' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Collplant Biotechnologies, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Collplant Biotechnologies position

In addition to having Collplant Biotechnologies in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Conservative Funds Thematic Idea Now

Conservative Funds
Conservative Funds Theme
Funds or Etfs that invest using buy-and-hold investment strategy in companies with consistent growth over many years of operation. The Conservative Funds theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Conservative Funds Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Collplant Biotechnologies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Collplant Biotechnologies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Collplant Biotechnologies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Collplant Biotechnologies Stock:
How To Invest In Collplant
Details
Is Collplant Stock a good investment?
Details
What is Collplant Biotechnologies' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Collplant Biotechnologies Correlation with its peers.
To learn how to invest in Collplant Stock, please use our How to Invest in Collplant Biotechnologies guide.
You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collplant Biotechnologies. If investors know Collplant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collplant Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Collplant Biotechnologies is measured differently than its book value, which is the value of Collplant that is recorded on the company's balance sheet. Investors also form their own opinion of Collplant Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Collplant Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collplant Biotechnologies' market value can be influenced by many factors that don't directly affect Collplant Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Collplant Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Collplant Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collplant Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY